Liu Ting, Lei Chao, Huang Qinhong, Song Weiqi, Li Chen, Sun Ning, Liu Zhihua
Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510799, People's Republic of China.
The First Clinical College, Guangzhou Medical University, Guangzhou, 511400, People's Republic of China.
Diabetes Metab Syndr Obes. 2024 Oct 7;17:3643-3656. doi: 10.2147/DMSO.S474034. eCollection 2024.
Obesity, which is associated with gut microbiota dysbiosis, low-grade chronic inflammation and intestinal barrier dysfunction, can cause a variety of chronic metabolic diseases. Phytochemical flavonoids have a variety of biological activities, among which there may be safe and effective anti-obesity solutions.
We tested a plant-derived flavonoid hesperidin and fecal microbiota transplantation (FMT) to alleviate diet-induced obesity. High-fat diet (HFD)-fed mice were treated with hesperidin (100 and 200 mg/kg BW) and FMT.
Results indicated that hesperidin had the effects of reducing obesity as indicated by reduction of body weight, fat accumulation and blood lipids, reducing inflammation as indicated by reduction of pro-inflammation factors including TNFα, IL-6, IL-1βand iNOS, and improving gut integrity as indicated by increasing colon length, reducing plasma gut permeability indicators iFABP and LBP, increased mRNA expression of mucus protein Muc2, tight junction p Claudin 2, Occludin and ZO-1 in the HFD-fed mice. The anti-obesity effects of hesperidin treatment have a dose-dependent manner. In addition, 16S rRNA-based gut microbiota analysis revealed that hesperidin selectively promoted the growth of while inhibiting and in the HFD-fed mice. Horizontal feces transfer from the normal diet (ND)-fed mice to the HFD-fed mice conferred anti-obesity effects and transmitted some of the HFD-modulated microbes.
We concluded that hesperidin and FMT both affect the reduction of body weight and improve HFD-related disorders in the HFD-fed mice possibly through modulating the composition of the gut microbiota.
肥胖与肠道微生物群失调、低度慢性炎症和肠道屏障功能障碍有关，可导致多种慢性代谢疾病。植物化学黄酮类化合物具有多种生物活性，其中可能存在安全有效的抗肥胖解决方案。
我们测试了一种植物源黄酮类化合物橙皮苷和粪便微生物群移植（FMT）对饮食诱导肥胖的缓解作用。用橙皮苷（100和200mg/kg体重）和FMT处理高脂饮食（HFD）喂养的小鼠。
结果表明，橙皮苷具有减轻肥胖的作用，表现为体重、脂肪堆积和血脂降低；具有减轻炎症的作用，表现为促炎因子TNFα、IL-6、IL-1β和诱导型一氧化氮合酶减少；具有改善肠道完整性的作用，表现为结肠长度增加、血浆肠道通透性指标iFABP和LBP降低，高脂饮食喂养小鼠中黏液蛋白Muc2、紧密连接蛋白Claudin 2、闭合蛋白和紧密连接蛋白1（ZO-1）的mRNA表达增加。橙皮苷治疗的抗肥胖作用呈剂量依赖性。此外，基于16S rRNA的肠道微生物群分析显示，橙皮苷在高脂饮食喂养的小鼠中选择性地促进了[未提及的微生物名称1]的生长，同时抑制了[未提及的微生物名称2]和[未提及的微生物名称3]。从正常饮食（ND）喂养的小鼠向高脂饮食喂养的小鼠进行水平粪便转移具有抗肥胖作用，并传递了一些高脂饮食调节的微生物。
我们得出结论，橙皮苷和FMT可能通过调节肠道微生物群的组成来影响高脂饮食喂养小鼠体重的减轻，并改善与高脂饮食相关的疾病。
